EP4004021A4 - Polypeptides having anti-senescent effects and uses thereof - Google Patents

Polypeptides having anti-senescent effects and uses thereof Download PDF

Info

Publication number
EP4004021A4
EP4004021A4 EP20844612.0A EP20844612A EP4004021A4 EP 4004021 A4 EP4004021 A4 EP 4004021A4 EP 20844612 A EP20844612 A EP 20844612A EP 4004021 A4 EP4004021 A4 EP 4004021A4
Authority
EP
European Patent Office
Prior art keywords
senescent
polypeptides
effects
senescent effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP20844612.0A
Other languages
German (de)
French (fr)
Other versions
EP4004021A2 (en
EP4004021B1 (en
Inventor
Alessandra ZONARI
Carolina Reis de OLIVEIRA
Edgar Andres OCHOA
Juliana Lott de CARVALHO
Lear BRACE
Mariana BORONI
Mylieneth GUIANG
Thuany de Alencar e SILVA
Octávio FRANCO
William Farias PORTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oneskin Inc
Uniao Brasileira De Educacao Catolica
Universidade de Brasília
Original Assignee
Uniao Brasileira De Educacao Catolica
Universidade Católica de Brasília
Oneskin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniao Brasileira De Educacao Catolica, Universidade Católica de Brasília, Oneskin Inc filed Critical Uniao Brasileira De Educacao Catolica
Publication of EP4004021A2 publication Critical patent/EP4004021A2/en
Publication of EP4004021A4 publication Critical patent/EP4004021A4/en
Application granted granted Critical
Publication of EP4004021B1 publication Critical patent/EP4004021B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
EP20844612.0A 2019-07-22 2020-07-22 Polypeptides having anti-senescent effects and uses thereof Active EP4004021B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962877164P 2019-07-22 2019-07-22
PCT/US2020/043033 WO2021016330A2 (en) 2019-07-22 2020-07-22 Polypeptides having anti-senescent effects and uses thereof

Publications (3)

Publication Number Publication Date
EP4004021A2 EP4004021A2 (en) 2022-06-01
EP4004021A4 true EP4004021A4 (en) 2023-09-27
EP4004021B1 EP4004021B1 (en) 2025-09-03

Family

ID=74194270

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20844612.0A Active EP4004021B1 (en) 2019-07-22 2020-07-22 Polypeptides having anti-senescent effects and uses thereof

Country Status (10)

Country Link
US (3) US12268746B2 (en)
EP (1) EP4004021B1 (en)
JP (2) JP2022541845A (en)
KR (1) KR20230096914A (en)
CN (1) CN114729015B (en)
BR (1) BR112022001229A2 (en)
ES (1) ES3049051T3 (en)
GB (1) GB2603645B (en)
TW (1) TWI862641B (en)
WO (1) WO2021016330A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134265A1 (en) 2017-01-17 2018-07-26 Forrest Michael David Therapeutic inhibitors of the reverse mode of atp synthase
WO2019012149A1 (en) 2017-07-13 2019-01-17 Forrest Michael David Therapeutic modulators of the reverse mode of atp synthase
EP4004021B1 (en) 2019-07-22 2025-09-03 Oneskin, Inc. Polypeptides having anti-senescent effects and uses thereof
CN116549325B (en) * 2022-01-27 2025-07-29 南京大学 Composition, preparation method, preparation and application thereof
CN114560912B (en) * 2022-03-28 2023-10-20 碧悦星泽(北京)生物医药科技有限公司 Polypeptide with anti-wrinkle function, compound and application thereof
CN115404257A (en) * 2022-06-24 2022-11-29 江西师范大学 Method for rapidly screening fish scale protein glue tyrosinase inhibitory peptide in high flux
CN115105423B (en) * 2022-07-18 2023-12-22 深圳浦瑞健康科技有限公司 Composition with anti-inflammatory and anti-allergic activities and application thereof
WO2024219827A1 (en) * 2023-04-17 2024-10-24 주식회사 하이센스바이오 Composition for inhibiting skin aging or treating wounds comprising cpne7 protein-derived peptide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070296A1 (en) * 2008-02-25 2011-03-24 Signum Biosciences, Inc. Topical compositions and methods for utilizing peptides containing lipid-modified cysteine-containing peptides
US20180015137A1 (en) * 2015-01-23 2018-01-18 Erasmus University Medical Center Rotterdam Anti-senescence compounds and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
WO1995006137A1 (en) 1993-08-27 1995-03-02 Australian Red Cross Society Detection of genes
AU3747000A (en) * 1999-03-23 2000-10-09 Human Genome Sciences, Inc. 49 human secreted proteins
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US6180349B1 (en) 1999-05-18 2001-01-30 The Regents Of The University Of California Quantitative PCR method to enumerate DNA copy number
US6569624B1 (en) 1999-08-12 2003-05-27 Wisconsin Alumni Research Foundation Identification of genetic markers of biological age and metabolism
US6287778B1 (en) 1999-10-19 2001-09-11 Affymetrix, Inc. Allele detection using primer extension with sequence-coded identity tags
DE10130800B4 (en) 2001-06-22 2005-06-23 Epigenomics Ag Method for the detection of cytosine methylation with high sensitivity
WO2003060122A1 (en) 2001-12-21 2003-07-24 Diadexus, Inc. Compositions and methods relating to urinary specific genes and proteins
US20030207280A1 (en) 2002-05-06 2003-11-06 Hsiung Hsiao Determination of physiological conditions defined in traditional chinese medicine
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20070259087A1 (en) 2003-06-11 2007-11-08 Novozymes A/S Antimicrobial Peptides
DE602004023624D1 (en) * 2003-06-11 2009-11-26 Novozymes As ANTIMICROBIAL PEPTIDES
WO2005007129A2 (en) * 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
US20060107345A1 (en) * 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
CN1569220A (en) * 2004-04-23 2005-01-26 大连帝恩生物工程有限公司 Application of gene recombined anti fungus peptide in the treatment of eumycetes infection
WO2006084132A2 (en) 2005-02-01 2006-08-10 Agencourt Bioscience Corp. Reagents, methods, and libraries for bead-based squencing
WO2008143679A2 (en) * 2006-06-01 2008-11-27 Verenium Corporation Nucleic acids and proteins and methods for making and using them
EP3574909B1 (en) * 2008-01-30 2026-03-04 Imbed Biosciences, Inc. Polyelectrolyte multilayer comprising silver for wound healing
WO2009133098A2 (en) * 2008-04-29 2009-11-05 Dsm Ip Assets B.V. β-LACTAM PRODUCING STRAINS
EP2977469A1 (en) 2008-08-28 2016-01-27 Dermtech International Determining age ranges of skin samples
GB0817121D0 (en) * 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
JP2010115131A (en) 2008-11-12 2010-05-27 Kao Corp Evaluation method and method for screening skin ageing improving agent and skin aging preventive
KR101117195B1 (en) 2009-07-27 2012-03-07 한국전기연구원 Apparatus and Method for measuring skin aging
US20110124111A1 (en) 2009-08-31 2011-05-26 Life Technologies Corporation Low-volume sequencing system and method of use
US10435743B2 (en) 2011-05-20 2019-10-08 The Regents Of The University Of California Method to estimate age of individual based on epigenetic markers in biological sample
WO2013192076A1 (en) 2012-06-18 2013-12-27 The Procter & Gamble Company Methods and models for assessing anti-aging benefits of agents
CA2920250A1 (en) 2013-08-02 2015-02-05 Stc.Unm Dna sequencing and epigenome analysis
CN105765083B (en) 2013-09-27 2021-05-04 加利福尼亚大学董事会 Methods for estimating the age of tissues and cell types based on epigenetic markers
EP3364949A4 (en) * 2015-10-22 2019-07-31 ModernaTX, Inc. ANTICANCER VACCINES
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
JP7184259B2 (en) * 2017-04-28 2022-12-06 学校法人藤田学園 Allergic antigens and their epitopes
WO2019074615A2 (en) 2017-09-14 2019-04-18 OneSkin Technologies, Inc. In vitro methods for skin therapeutic compound discovery using skin age biomarkers
EP4004021B1 (en) 2019-07-22 2025-09-03 Oneskin, Inc. Polypeptides having anti-senescent effects and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070296A1 (en) * 2008-02-25 2011-03-24 Signum Biosciences, Inc. Topical compositions and methods for utilizing peptides containing lipid-modified cysteine-containing peptides
US20180015137A1 (en) * 2015-01-23 2018-01-18 Erasmus University Medical Center Rotterdam Anti-senescence compounds and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021016330A2 *

Also Published As

Publication number Publication date
EP4004021A2 (en) 2022-06-01
JP2022541845A (en) 2022-09-27
GB202200959D0 (en) 2022-03-09
EP4004021B1 (en) 2025-09-03
CN114729015A (en) 2022-07-08
US12268746B2 (en) 2025-04-08
US20210038729A1 (en) 2021-02-11
TWI862641B (en) 2024-11-21
TW202118508A (en) 2021-05-16
WO2021016330A2 (en) 2021-01-28
US12268747B2 (en) 2025-04-08
GB2603645B (en) 2023-03-01
BR112022001229A2 (en) 2022-06-14
JP2025123221A (en) 2025-08-22
ES3049051T3 (en) 2025-12-12
US20250235542A1 (en) 2025-07-24
CN114729015B (en) 2024-01-12
WO2021016330A3 (en) 2021-03-04
US20240342290A1 (en) 2024-10-17
GB2603645A (en) 2022-08-10
KR20230096914A (en) 2023-06-30

Similar Documents

Publication Publication Date Title
EP3917517A4 (en) Compounds and uses thereof
EP4004021A4 (en) Polypeptides having anti-senescent effects and uses thereof
EP3813861A4 (en) Heparin-associated polypeptides and uses thereof
EP4006048A4 (en) Novel micropeptide hmmw and application thereof
EP4037670A4 (en) 5-fluoronicotinamide derivatives and uses thereof
IL287782A (en) Cd33-binding polypeptides and uses thereof
EP3882263A4 (en) Glucagon-derived peptide and use thereof
EP3993818A4 (en) Cd38-binding agents and uses thereof
EP4081235A4 (en) Heparin-associated polypeptides and uses thereof
EP4028502A4 (en) N-acyl-tyrosine derivatives and uses thereof
EP3993874A4 (en) Cd38-binding agents and uses thereof
AU2020234373A1 (en) Novel peptide and use thereof
EP3996737A4 (en) Peptides and uses thereof
HK40068899A (en) Clec12a-binding polypeptides and uses thereof
HK40068898A (en) Cd33-binding polypeptides and uses thereof
HK40068897A (en) Cd123-binding polypeptides and uses thereof
AU2019903255A0 (en) Polypeptides and uses thereof
HK40050222A (en) Ox40-binding polypeptides and uses thereof
AU2019901599A0 (en) Polypeptides and uses therefor
HK40082821A (en) Fluoroalkyl-oxadiazoles and uses thereof
AU2018904117A0 (en) Polypeptides and uses thereof
HK40068941A (en) Thiosemicarbazates and uses thereof
AU2019902436A0 (en) Peptides and uses thereof
AU2019902437A0 (en) Peptides and uses thereof
EP3938360A4 (en) Calixcrowns and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220125

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNIVERSIDADE CATOLICA DE BRASILIA

Owner name: UNIAO BRASILEIRA DE EDUCACAO CATOLICA

Owner name: ONESKIN, INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230604

A4 Supplementary search report drawn up and despatched

Effective date: 20230829

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/17 20060101ALI20230823BHEP

Ipc: A61K 38/08 20190101ALI20230823BHEP

Ipc: A61P 3/02 20060101ALI20230823BHEP

Ipc: A61P 17/02 20060101ALI20230823BHEP

Ipc: A61K 38/10 20060101ALI20230823BHEP

Ipc: C07K 14/41 20060101AFI20230823BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240419

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250221

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ONESKIN, INC.

Owner name: UNIAO BRASILEIRA DE EDUCACAO CATOLICA

Owner name: UNIVERSIDADE CATOLICA DE BRASILIA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020058199

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 3049051

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20251212

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20250903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251203

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250903

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251203

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1832970

Country of ref document: AT

Kind code of ref document: T

Effective date: 20250903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260103